Vaxart appoints Jeroen Grasman as CFO, replaces Phillip Lee

Vaxart, Inc.

CFO Phillip Lee resigns effective upon appointment of successor; no disagreement; remains as non-executive employee through June 1, 2025.
Jeroen Grasman appointed CFO effective May 19, 2025; previously CFO at AltruBio, VP Finance at PACT Pharma and Genentech.
Grasman receives base salary $435K, target bonus 40%, option for 1M shares vesting over 48 months, RSU for 350K shares.
Lee forfeits unvested equity upon termination; no termination benefits.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeroen Grasman

Chief Financial Officer

VXRT · Vaxart, Inc.

Effective: 2025-05-19
Filed: May 13, 2025, 7:59 PM ET

On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.

Departed

Phillip Lee

Chief Financial Officer

VXRT · Vaxart, Inc.

Effective: 2025-05-19
Successor: Jeroen Grasman
Filed: May 13, 2025, 7:59 PM ET

On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeroen Grasman was appointed as Chief Financial Officer at Vaxart, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Phillip Lee resigned as Chief Financial Officer at Vaxart, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.

View on SEC.gov

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-016500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.